CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

NCT03567889 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT186

EST. COMPLETION2027-12

Conditions

Melanoma Stage IIIBMelanoma Stage IIICMelanoma Stage IIID

Interventions

DaromunSurgeryAdjuvant therapy

Study details

SPONSORPhilogen S.p.A.

START DATE2018-09-20

Related company profiles

Philogen

PHIL.MI

Primary source

ClinicalTrials.gov record NCT03567889 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT03567889
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record